MRNA
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Moderna, Inc. - Common Stock (MRNA) [ST]
www.modernatx.com ↗▼ 0.76%
prev close
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Congressional Trades
3
All tracked trades
Members Trading
3
Unique members
Net Activity
-3
0 buys · 3 sells
Members Who Traded This Stock
3 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2025-04-08 | MRNAModerna, Inc. - Common Stock | Sell | $1,001 - $15,000 | 391d ago | — | |
| 2025-01-15 | MRNAModerna, Inc. - Common Stock | Sell | $1,001 - $15,000 | 476d ago | — | |
| 2024-02-01 | MRNAModerna, Inc. - Common Stock | Sell | $1,001 - $15,000 | 818d ago | — |
2025-04-08
Rob Bresnahan
MRNA
Amount
$1,001 - $15,000
Filed
391d ago
2025-01-15
Julie Johnson
MRNA
Amount
$1,001 - $15,000
Filed
476d ago
2024-02-01
Josh Gottheimer
MRNA
Amount
$1,001 - $15,000
Filed
818d ago
Recent News
Powered by Polygon.io
Moderna Reports Strong 5-Year Cancer Vaccine Data, Expands CEPI Partnership; Stock Falls
Anterix Stock Is Up 140%. Here's Why One Investor Just Bought $15.8 Million
Synovial Sarcoma Clinical Trial Pipeline Accelerates as 15+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
CytomX Therapeutics to Present at Upcoming June Investor Conferences
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally
Trade Timeline
Congressional activity, newest first
Rob Bresnahan
2025-04-08 · Sale
$1,001 - $15,000
Julie Johnson
2025-01-15 · Sale
$1,001 - $15,000
Josh Gottheimer
2024-02-01 · Sale
$1,001 - $15,000